KADCYLA is the first HER2-targeted treatment of its kind. It is made up of two cancer-fighting agents in one drug:
When you take KADCYLA, you are getting both a HER2-targeted treatment and a chemotherapy, at the same time.
Learn about how well KADCYLA worked for people with HER2+ early breast cancer and what potential side effects to expect.
Learn about how well KADCYLA worked for people with HER2+ metastatic breast cancer and what potential side effects to expect.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.